Background: Chronically elevated interleukin-6 (IL-6) is implicated in obesity-associated pathologies, where a proportion of this cytokine is derived from adipose tissue. Proinflammatory prostaglandins, which regulate this cytokine elsewhere, are also produced by this tissue. Objective: To investigate whether constitutively active cyclooxygenase (COX)/prostaglandin (PG) pathway in white adipose tissue (WAT) is responsible for basal IL-6 production. Design: The effect of acetylsalicylic acid (ASA), an inhibitor of COX, on IL-6 was assessed in human subjects and mice. COX, downstream PG synthase (PGS) activity and PG receptor signalling were determined in subcutaneous (SC), gonadal (GN) WAT and adipocytes. Methods and Results: In obese humans, low-dose ASA (150 mg day À1 for 10 days) inhibited systemic IL-6 and reduced IL-6 release from SC WAT ex vivo (0.2 mM). Similarly, in mice, ASA (0.2 and 2.0 mg kg À1 ) suppressed SC WAT 6-keto-PGF 1a (a stable metabolite of prostacyclin) and IL-6 release. Although both COX isoforms are comparably expressed, prostacyclin synthase expression is higher in GN WAT, with levels of activity correlating directly with IL-6. Both ASA (5 mM) and NS-398 (COX-2 selective inhibitor p1 mM), but not SC-560 (COX-1 selective inhibitor p1 mM), attenuated IL-6 release from murine WAT in vitro and abolished its depot differences. Prostacyclin receptor (IP) and, to a lesser extent, PGE 2 (EP2 and EP4) receptor agonists elevated the release of IL-6 from adipocytes. Conclusions: In adipose tissue, constitutive COX-2-coupled prostacyclin triggers the release of basal IL-6, which in obese subjects is significantly dampened by ASA ingestion, thus offering a novel, modifiable pathway to regulate the potentially pathological component of this cytokine.
Introduction
Interleukin-6 (IL-6) is a pleiotrophic cytokine with immunomodulatory and metabolic functions. The physiological consequences of acute elevation in IL-6 levels appear at odds with those that are associated with chronic, low-level elevation of this cytokine. [1] [2] [3] Collectively, the data suggest that acute increases in IL-6 are beneficial, 2 whereas in obesity-associated pathologies, such as type 2 diabetes mellitus and coronary artery disease, there are close associations between chronically elevated circulating IL-6 levels and insulin resistance, high triglycerides, low high-density lipoprotein cholesterol and elevated blood pressure, C-reactive protein and fibrinogen. 4, 5 Furthermore, chronic IL-6 elevation may also have a direct and causative role in the atherosclerotic process. Indeed, IL-6 is expressed within atherosclerotic plaques 6 and induces a number of procoagulant 7 and chemotactic properties 8 while concurrently increasing the release of adhesion molecules by the endothelium 9 and inducing oxidative stress. 10 Finally, within the adipose tissue, IL-6 has autocrine/paracrine effects on adipogenesis, and on tissue glucose and lipid homoeostasis. 4, 5 In obesity, the expanded adipose tissue, 11 especially in visceral depots, 12, 13 contributes significantly to both the local and systemic IL-6 concentrations. Furthermore, adipose tissue production of IL-6 appears unique, in that a component of it is constitutive and local concentrations far exceed those seen systemically, perhaps explaining its adverse effects. Understanding the molecular mechanisms of this basal release could lead to targeted dietary and pharmacological strategies to modulate this cytokine in obesityassociated pathologies. Prostanoids, the cyclooxygenase (COX) products derived from C-20 unsaturated fatty acids, 14 and especially prostaglandins (PGs), regulate IL-6 production in several tissues. [15] [16] [17] Arachidonic acid (20:4 n-6) is the most abundant of the prostanoid precursor fatty acids in mammals and a substrate for series 2 prostanoids. 14 Arachidonic acid is released from membrane phospholipids in response to various physiological and pathological stimuli by the action of phospholipase A2, followed by the actions of COX and the respective downstream PG synthases. 14 The prostanoids thus formed are, at least in part, released outside of the cells and act via specific G-protein-coupled rhodopsin-type receptors: TXA 2 Acetylsalicylic acid (ASA), in addition to being the most widely used anti-inflammatory agent, also has cardioprotective effects. 22 The principal mechanism traditionally thought to be responsible for this effect is through the inhibition of PG synthesis and COX-1-mediated platelet aggregation. 23 However, the inhibition of COX does not fully account for the spectrum of activities of this drug, and there is evidence that ASA may inhibit cytokine synthesis, both in vitro and in vivo, through both prostaglandindependent and -independent mechanisms, such as inhibition of nuclear translocation of transcription factors. 24 As spontaneous IL-6 production by the adipose tissue ex vivo 12, 25 implies prior in vivo stimulation, the aim of this study was to utilize the COX inhibitors to investigate the role of prostaglandins in mediating the spontaneous/constitutive IL-6 production from white adipose tissue (WAT).
Materials and methods
Human in vivo study Twenty-two non-diabetic Caucasian subjects were studied in the post-absorptive state in the morning between 0800 and 1100 hours after fasting overnight on two separate occasions, before and after 10 days of ASA therapy (150 mg day À1 Human adipose tissue in vitro study Subcutaneous (SC) adipose tissue was obtained from five morbidly obese, non-diabetic, Caucasian patients undergoing laparoscopic bariatric surgery. The tissue was used for organ culture to assess the effect of ASA treatment in vitro on adipose IL-6 secretion as outlined below.
All subjects gave informed written consent for these studies, which had earlier been approved by the local ethics committee.
Exclusion criteria. (i) Current treatment with ASA, nonsteroidal anti-inflammatory drugs, steroids, warfarin, heparin, angiotensin-converting enzyme inhibitors, statins or other agents known to affect PGs or cytokine synthesis; (ii) coronary artery disease; (iii) connective tissue disease or other inflammatory conditions more likely to affect cytokine levels; (iv) malignancy or other terminal illness; (v) uncontrolled hypertension and (vi) earlier gastric ulcer or gastrointestinal haemorrhage.
Blood sampling. Blood samples were obtained from the antecubital vein by venepuncture, separated by centrifugation and analyzed for plasma glucose, serum total cholesterol, plasma IL-6 and tumour necrosis factor-a.
Murine studies
Male, obesity-prone C57BL6/J mice were obtained at 6 weeks of age (Harlan UK Ltd., Bicester, Oxon, UK) and held in accordance with Home Office regulations. Studies were carried out when animals were 11-12 weeks of age.
ASA administration in vivo ASA (Sigma, Poole, Dorset, UK) was ground to a fine powder using a pestle and mortar and suspended in vehicle (1% tragacanth, Sigma). ASA (0.2 or 2.0 mg kg À1 ) or vehicle (control group) was given via oral gavage every day at approximately 1000 hours for 7 days. On the seventh day, the corresponding drugs were given and 1 h later the mice were killed. Each group consisted of 14 mice. SC dorsolumbar and gonadal (GN, epididymal) adipose tissue was obtained from all mice.
Adipose tissue was used for (i) tissue lysate preparation; (ii) western blot analysis; (iii) organ cultures for assessing cytokine release; (iv) primary cultures of adipocytes and (v) PG extraction, as outlined below.
(i) Preparation of tissue lysates: Approximately 0.2 g of tissue of each depot was crushed and lysed in protein lysis buffer (1% Triton X-100, Tris-HCl, pH 7.6, 150 mM NaCl) supplemented with protease inhibitors at 100 mM (Complete; Boehringer Mannheim, UK). The homogenate was Aspirin inhibits IL-6 secretion by white fat NC Ogston et al centrifuged at 14 000 r.p.m. for 30 min and the infranatant recovered and used for western blot analysis, tissue IL-6 levels and PGs, as outlined below.
(ii) Western blot analysis: The protein content of the tissue lysate was estimated with a kit from Bio-Rad (Hemel Hempstead, Herts, UK) and 20 mg of total protein was separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis. Gels were blotted onto polyvinylidene fluoride membranes and blocked with 5% non-fat dried milk and probed with polyclonal antibodies against murine COX-1, COX-2, prostacyclin synthase (Cayman Chemical, Ann Arbor, MI, USA) and a-tubulin (Sigma). Secondary antibodies conjugated to horseradish peroxidase were from Amersham Biosciences (Little Chalfont, UK). Antigen-antibody complexes were detected by chemiluminescence with an ECL kit (Amersham Biosciences, Little Chalfont, UK) and blots exposed to high-performance chemiluminescence film (Hyperfilm ECL; Amersham Biosciences).
(iii) Organ culture of adipose tissue: Human SC adipose tissue samples (0.2 g) were finely minced and incubated in serumfree medium, enriched with albumin, glutamine and phenol red (Cellgro, Mediatech Inc., Manassas, VA, USA) for 24 h at 37 1C/5% CO 2 in the presence or absence of 0.2 mM ASA.
To study COX expression and activity, approximately 0.2 g of murine tissue from the SC and GN depot was finely minced and incubated in serum-free medium with albumin, glutamine and phenol red (Cellgro, Mediatech Inc.) for 5 h at 37 1C/5% CO 2 in the absence of additives or with COX inhibitors (non-selective COX inhibitor ASA at 0.2 and 5.0 mM; selective COX-2 inhibitor NS-398 or selective COX-1 inhibitor SC-560 at 0.01 and 1.0 mM).
At the end of the incubation, both human and murine tissues were snap-frozen in liquid N 2 and stored at À80 1C along with the culture supernatant. This method has been validated and tissue shown to be viable and responsive to hormones for up to 2 weeks. 26 ASA was obtained from Sigma. NS-398, SC-560 and PG receptor agonists (sulprostone, butaprost, PGE 1 alcohol and carbacyclin) were from Alexis Corporation (Nottingham, UK).
(iv) Differentiation of adipocytes in primary culture: The SC tissue was digested with Type II collagenase (2 mg ml À1 , Sigma) at 37 1C for 45 min in a shaker-heater. The tissue digest was filtered (260 mm metal gauze; Sigma) and the adipocyte layer separated from the resulting cell pellet by centrifugation (1500 r.p.m. for 15 min). The stroma-vascular cell pellet was washed and re-suspended in medium (Dulbecco's modified Eagle's medium, DMEM:F12; GibcoBRL, Glasgow, UK) containing 10% fetal calf serum (GibcoBRL). Cells were seeded at 6 Â 10 4 cells/ml and on confluence (2-3 days after seeding), the medium was changed to adipogenesis induction media consisting of high-glucose DMEM containing 10% bovine calf serum (Perbio, Paisley, UK) and 1% penicillin/streptomycin supplemented with dexamethasone (0.1 mM), isobutylmethylxanthine (0.5 mM) and insulin (5 mg ml
À1
; all from Sigma).
After 72 h incubation with the induction media, isobutylmethylxanthine and dexamethasone were withdrawn and the medium was changed every 2 days. Cells were used at 7-10 days post-induction of adipogenesis when over 90% of them were lipid laden. Prostaglandin receptor agonists, sulprostone, butaprost, PGE 1 alcohol and carbacyclin, were used to treat these primary differentiated adipocytes for 24 h at 37 1C/5% CO 2 . Time-(3, 6 and 24 h) and dose-(0, 0.01, 0.1, 1 and 2 mM) response experiments were performed with PGE 1 alcohol in 3T3L1 adipocytes. Maximum response was attained after 24 h incubation, with the agonist at 1 mM. Similar dose-response results were obtained for carbacyclin at 1 mM after 24 h incubation. Therefore, this concentration was used for further experiments with primary adipocytes. At the end of the incubation cell culture, supernatant was stored to determine IL-6 concentrations. The GN tissue was not used for this purpose because of its poor differentiation in vitro.
(v) PG extraction: Tissue lysate of 100 ml was diluted in methanol and water and then acidified to pH 3.5. Sep-Pak Vac 3 cc (500 mg) C18 cartridges (Waters, Elstree, UK) were preconditioned, the sample was applied and the column washed. The sample was eluted with methyl formate and the eluate evaporated in a Speed Vac. The residue was reconstituted in 0.5 ml of Cellgro.
Assays
Plasma glucose concentration was assayed with glucose oxidase reagent (Beckman, Brea, CA, USA) and serum total cholesterol was assayed with commercial reagents (Roche Diagnostics, Herts, UK). High-sensitivity two-site ELISAs were used to determine human tumour necrosis factor-a and IL-6 concentrations in plasma. Normal-sensitivity human and mouse IL-6 ELISAs were used to measure levels in the organ or cell culture supernatants and tissue lysates (R&D Systems, Oxon, UK). PGE 2 and 6-keto-PGF 1a , a stable metabolite of prostacyclin, were assayed by direct enzyme immunoassay (Amersham Biosciences). Activities of prostacyclin and PGE 2 synthase were measured as 6-keto-PGF 1a or PGE 2 release and expressed in nanogram of the PG released per gram of adipose tissue per hour. All assays had inter-and intra-assays coefficient of variation of less than 10%.
Statistical analyses
Data were analysed using Microsoft Excel or SPSS version 14 for Windows software (Statistical Package for the Social Sciences, SPSS UK Ltd., Chertsey, UK). Data in the text are expressed as mean (s.d.) unless otherwise specified and as mean (s.e.m.) in figures. Comparison of depot-specific differences was carried out by paired t-test and of control versus treatment by unpaired t-test or the Mann-Whitney U-test for non-parametric data. Correlations between IL-6 and PGs were determined by the Spearman rank regression analysis. Significance was defined as Po0.05.
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Results
Effect of ASA on plasma cytokines in vivo in human volunteers and on human adipose tissue secretion of IL-6 in vitro Baseline clinical characteristics of the volunteers in the in vivo study are displayed in Table 1 . By definition, the lean and obese subgroups differed in terms of BMI and waist circumference, whereas they were comparable in terms of sex, age, fasting plasma glucose, total cholesterol and blood pressure.
Ten However, in the obese subjects, there was a significant reduction in systemic IL-6, but not in tumour necrosis factora (Figure 1) . Furthermore, there were no significant changes in systemic levels of either cytokine in the lean subjects ( Figure 1) .
As the subjects were normoglycaemic and normolipidaemic, the change in IL-6 in response to ASA in the obese was postulated to be, at least in part, due to the suppression of basal adipose tissue production of this cytokine. We tested this hypothesis in SC WAT from five morbidly obese female subjects (age 44.0 (6. Thus, in obese human volunteers, low-dose ASA significantly decreased circulating IL-6 and also inhibited its release from SC WAT at 0.2 mM in vitro.
Effect of ASA on adipose tissue synthesis and secretion of PGs and IL-6 in mice in vivo Adipose tissue obtained from mice treated with vehicle or ASA (0.2 or 2.0 mg kg À1 ) for 7 days was assessed for tissue content and release of IL-6, as well as of PGE 2 and 6-keto-PGF 1a , a stable metabolite of prostacyclin. Although SC WAT 6-keto-PGF 1a content was significantly inhibited by 2.0 mg kg À1 ASA in vivo, there were no changes in tissue PGE 2 or IL-6 (Figures 2a-c) . However, the release of 6-keto-PGF 1a and IL-6 from SC WAT was significantly inhibited at both doses of ASA used (Figures 2e and f) . PGE 2 secretion was not affected (Figure 2d ). This apparent discrepancy between tissue content and the release of IL-6 may be explained by data that suggest that, in most cells, cytokine mRNA is induced in response to stimuli followed by active secretion, rather than storage within tissues. 27 Plasma levels of IL-6
were not investigated because high-sensitivity assays for mouse IL-6 are not available. Therefore, in mice, ultra-low doses (0.2 and 2 mg kg ) of ASA were sufficient to decrease the release of prostacyclin and IL-6, but not PGE 2 , from SC WAT.
Effect of COX inhibition on murine adipose tissue PGs and IL-6 secretion in vitro When IL-6 release was measured using organ cultures, the GN depot released significantly more IL-6 than the SC depot (Figure 3a) , and there was significant correlation between the levels from the two depots (r ¼ 0.65; Po0.001), perhaps suggesting regulation by common mechanisms. In vitro treatment of adipose tissue with ASA at 5 mM reduced IL-6 secretion from GN depot to approximately 33% of basal levels and from SC adipose tissue to approximately 42% of basal levels (Figure 3a) . NS-398 (COX-2 selective: X0.01 mM) also inhibited IL-6 release from the GN depot to approxi- 
P=0.06
Cytokine concentration (pg ml -1 ) IL-6 TNFα α Figure 1 Inhibition of systemic interleukin-6 (IL-6) by acetylsalicylic acid (ASA) treatment in obese subjects in vivo. Plasma IL-6 and tumour necrosis factor (TNF)a were determined by ELISA (R&D Systems) in Caucasian lean (n ¼ 11) and obese (n ¼ 11) subjects before and after ASA therapy (150 mg day À1 for 10 days). Data are shown as mean ± s.e.m. Aspirin inhibits IL-6 secretion by white fat NC Ogston et al mately 33% of basal levels and from the SC depot by about 30% (Figure 3b ). SC-560 (COX-1 selective: 0.1-1.0 mM) did not significantly alter adipose IL-6 secretion (data not shown). COX-2 inhibition abolished the depot-specific difference in the IL-6 release (Figures 3a and b) . Both COX-1 and COX-2 proteins were abundant and constitutive in both fat depots (data not shown).
Possible involvement of endogenous adipose PGs in fat depot-specific differences in IL-6 release in mice Significant amounts of both 6-keto-PGF 1a and PGE 2 were released by adipose tissue organ cultures (see above), suggesting that both prostacyclin synthase and PGE 2 synthase are active in the tissue. However, prostacyclin synthase activity and protein expression were higher in GN Aspirin inhibits IL-6 secretion by white fat NC Ogston et al than in SC tissue, whereas PGE 2 synthase activity did not differ significantly between the two depots (Figures 4a-c) .
The endogenous release of 6-keto-PGF 1a from both depots showed a significant positive correlation to adipose IL-6 release (Figures 5a and b) . Conversely, endogenous PGE 2 release was statistically unrelated to that of IL-6 release (data not shown). PG receptor agonists and IL-6 release We postulated that PG receptors using cAMP as a second messenger (the EP2 and EP4 receptor isoforms for PGE 2 Aspirin inhibits IL-6 secretion by white fat NC Ogston et al in intracellular Ca 2 þ levels (see Introduction) should mediate IL-6 production. This hypothesis was tested by measuring IL-6 release from murine adipocytes differentiated in primary culture ( Figure 6 ) in the presence of specific receptor agonists: sulprostone (EP1 agonist), butaprost (EP2 agonist), PGE 1 alcohol (mixed EP2/4 agonist) or carbacyclin (IP receptor agonist). Sulprostone did not significantly alter IL-6 release. Butaprost, and to a greater degree PGE 1 alcohol, augmented IL-6 release, perhaps suggesting greater abundance of the EP4 receptor in adipocytes. However, carbacyclin induced IL-6 more potently than all the other receptor agonists studied, confirming the effect of endogenous prostacyclin on the release ( Figure 6 ). Treatment of differentiated primary adipocytes for 4 h with the cell-permeable analogue of cAMP, dibutyryl cAMP (100 mM), significantly increased IL-6 secretion (median {interquartile range} 444.5 {376.8-852.0} versus 3233 {1706-4109} pg ml À1 per 10 6 cells per 24 h; Po0.01), whereas induction of intracellular Ca 2 þ by ATP or inhibition of its entry from extracellular pools with NiCl 2 had no effect on IL-6 release (data not shown).
Discussion
We show, for the first time, the reduction of circulating IL-6 by ASA (150 mg daily for 10 days) in obese, non-diabetic subjects, which is not apparent in lean volunteers, implying a prostanoid-related mechanism linking inflammation and obesity. The direct effects of ASA on IL-6 have been studied earlier in different populations and yielded variable results. [28] [29] [30] [31] [32] A medium dose of aspirin (300 mg daily) reduced systemic IL-6 in patients with stable angina pectoris, 28 but not in those with hypercholesterolaemia. 29 Also the same dose of aspirin for 12 weeks reduced peripheral blood mononuclear cell production of IL-6 in patients with active vitiligo. 30 As IL-6 is a key regulator of C-reactive protein, our results may also indirectly support those obtained in the Physicians Health Study, where it was observed that the beneficial effects of ASA were significant only in the subjects with high circulating C-reactive protein levels, suggesting a possible anti-inflammatory effect in these patients. 31 However, in a large cross-sectional study of elderly, non-diabetic men, low-dose ASA therapy (75 mg daily) was not associated with a reduction in serum IL-6, C-reactive protein or serum amyloid A. 32 The more pronounced effect of ASA on systemic IL-6 in individuals with higher BMI suggests a possible protective, anti-inflammatory role for ASA specifically in obese subjects, perhaps targeting increased adiposederived IL-6 in these subjects.
As we were unable to obtain adipose tissue in our human in vivo study and in order to explore the effect of ingested ASA on the adipose tissue, ultra-low doses, around 2-to 10-fold lower than those described earlier, 33 were used in mice so as to be comparable with those used in humans. Even at these doses, ASA inhibited the release of 6-keto-PGF 1a and IL-6, although not PGE 2 , from murine WAT. Tissue 6-keto-PGF 1a also decreased but only at the higher dose used (2 mg kg
À1
), perhaps suggesting that the PGs and IL-6 are formed and released rapidly rather than stored by the tissue. 27 We found that the pharmacological inhibition of COX with ASA reduced circulating IL-6 levels in vivo and significantly suppressed IL-6 production from human and mouse WAT in vitro. Specific inhibition of COX-2 ex vivo also reduced adipose IL-6 and abolished the differences seen between SC and GN adipose tissue in mice. Basal IL-6 secretion from adipose tissue correlated with endogenous prostacyclin synthase activity. Furthermore, prostacyclin synthase protein and activity were greater in GN than in SC adipose tissue in mice. In our study, endogenous adipose PGE 2 synthesis and secretion were unrelated to IL-6. However, given that both COX isoforms are constitutively expressed, these data suggest that in this tissue, as in endothelial and smooth muscle cells, 34 prostacyclin synthesis is more coupled to COX-2 activity and drives the IL-6 secretion. Because the endogenous ligands for the PGs receptors, prostacyclin and especially PGE 2 , are quite unstable, synthetic receptor agonists were used to clarify the role of receptor signalling and to characterize the receptors involved in the release of IL-6 from adipocytes differentiated in primary culture. In adipocytes, EP2, EP4 and IP receptor agonists acting through the elevation of intracellular cAMP induce IL-6 release. TXB 2 -mediated IL-6 release has also been reported through a similar mechanism in astrocytes. 35 Carbacyclin (IP receptor agonist), which is a powerful inducer of IL-6, has earlier been shown to inhibit leptin Aspirin inhibits IL-6 secretion by white fat NC Ogston et al release from adipose tissue. 36 The EP4 and IP receptors are more abundant in the stroma-vascular fraction of adipose tissue, than in adipocytes themselves, 37 perhaps explaining the greater release of IL-6 from the non-adipocyte fraction. That these PG receptors also mediate IL-6 release from other cells is apparent. [15] [16] [17] For instance, in symptomatic atherosclerotic lesions, increased expressions of IL-6 protein and mRNA, as well as EP4 expression have been reported. 38 Perhaps in these lesions, as seen in our in vitro studies, IL-6 release is induced by PGE 2 via an EP4-mediated pathway. However, in peritoneal rat macrophages, like in adipose tissue, arachidonic acid stimulates IL-6 release through a prostacyclin-mediated mechanism and prostacyclin, as well as prostacyclin agonists, stimulated IL-6 release. 39 In conclusion, this study shows that ASA therapy suppresses even the modest systemic elevation in IL-6 levels in obese subjects, rendering them comparable with those seen in lean individuals. Although both COX isoforms are constitutively active and produce vasoactive prostanoids, it is the production of prostacyclin that regulates the secretion of the IL-6, with basal adipose tissue IL-6 secretion largely induced by COX-2-dependent prostacyclin production both in vitro and in vivo. Furthermore, depot-specific differences in expression and activity of prostacyclin synthase may explain the greater release of IL-6 from GN WAT. Dietary and pharmacological interventions that lower the activity of COX-mediated prostacyclin synthase in adipose tissue are therefore likely to lead to local inhibition of IL-6 production. Our novel observations of the susceptibility of the adipose tissue COX/PG pathway to ASA inhibition, as well as the fat depot-specific expression of prostacyclin synthase and the production of prostacyclin have important implications not only for the control of IL-6 release but perhaps also for other important prostacyclin-regulated functions in adipose tissue, such as adipogenesis 19 and local adipose tissue blood flow.
Considering the limited amount of literature on the effects of aspirin on adipose tissue and obesity, our observations suggest that a more thorough evaluation of this drug in obese humans may be timely.
